anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Tranexamic acid
Trial phase: Phase 4
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: Patients receive TXA before and during the surgical case.

Tranexamic Acid : For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
Eligibility criteria:
Inclusion Criteria:

Undergoing thoracic and/or lumbar surgery for correction of adolescent idiopathic scoliosis, neuromuscular scoliosis, or adult deformity for correction of condition via posterior spinal fusion of 6 levels or greater.

Exclusion Criteria:

No renal dysfunction identified by elevated blood urea nitrogen (BUN) and creatinine (CR) or BUN to CR ratio greater than 20:1
Hold religious and/or other beliefs limiting blood transfusion
Currently use anti-coagulant medication or have past medical history leading to abnormal coagulation profile pre-operatively
Significant past medical history preventing the use of TXA or EACA described in the protocol
Intervention: Telapristone acetate
Trial phase: Phase 2
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](c1ccc(N(C)C)cc1)C1=C3CCC(=O)C=C3CC[C@]12[H]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 4
Group description: 25 mg Proellex: one 25 mg capsules
Eligibility criteria:
Inclusion Criteria:

Four subjects at one site whom have completed ZPU 003 Ext 1 study

Exclusion Criteria:

All other subjects
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: 25 ml Intravenous
Eligibility criteria:
Inclusion Criteria:

Male or female patient 50 years of age or older;
A diagnosis of COPD defined by American Thoracic Society-European Respiratory Society criteria
Current or former smoker with a smoking history of greater than or equal to 10 pack-years;
A post-bronchodilator forced expiratory volume in one second (FEV1) greater than or equal to 30% predicted and less than or equal to 80% predicted; AND
A post-bronchodilator FEV1/forced vital capacity ratio less than 70%; and clinically stable COPD.

Exclusion Criteria:

Any patient who has a concomitant disease that might interfere with study procedures or evaluation;
Inability to perform resistive breathing maneuvers; OR
Any current use of a narcotic medication.
Intervention: Colchicine
Trial phase: Phase 1
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: Each subject received one 0.6 mg colchicine tablet on Day 1 at after an overnight fast, followed by a washout period of 14 days.
Eligibility criteria:
Inclusion Criteria:

Healthy adults 18-45 years of age
Non-smoking and non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)
Body mass index (BMI) greater than or equal to 18 and less than or equal to 32, inclusive
Hemoglobin greater than or equal to 11.5g/dL

Exclusion Criteria:

Recent participation (within 28 days) in other research studies
Recent significant blood donation or plasma donation
Pregnant or lactating
Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)
Recent (2-year) history or evidence of alcoholism or drug abuse
History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study
Drug allergies to colchicine
Intolerance or food allergy to Seville orange juice
Intervention: Colchicine
Trial phase: Phase 1
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: On the morning of Day 1, subjects received a single dose of colchicine 0.6 mg after an overnight fast, followed by a 14 day washout period.
Eligibility criteria:
Inclusion Criteria:

Healthy adults 18-45 years of age
Non-smoking and non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)
Body mass index (BMI) greater than or equal to 18 and less than or equal to 32, inclusive
Hemoglobin greater than or equal to 11.5g/dL

Exclusion Criteria:

Recent participation (within 28 days) in other research studies
Recent significant blood donation or plasma donation
Pregnant or lactating
Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)
Recent (2-year) history or evidence of alcoholism or drug abuse
History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study
Drug allergies to colchicine or atorvastatin or any other HMG-CoA reductase inhibitor agents (i.e. simvastatin, lovastatin, rosuvastatin, fluvastatin, and pravastatin)
Intervention: Tenofovir
Trial phase: Phase 4
SMILES: C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: switch from Combivir to Truvada
Eligibility criteria:
Inclusion Criteria:

infection with human immunodeficiency virus (HIV) with undetectable viral load
on Combivir or trizivir
able to exercise and sign consent

Exclusion Criteria:

other active illness
contraindication to magnetic resonance imaging (MRI) scanning or maximal exercise.
Intervention: Desmopressin
Trial phase: Phase 2
ATC code: H01BA02
SMILES: N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes

DDAVP injection (desmopressin acetate): 0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
Eligibility criteria:
Inclusion Criteria:

Spontaneous intracerebral hemorrhage as documented by head CT scan
Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion Criteria:

International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
History of von Willebrand disease
Pregnancy
Known hypersensitivity to DDAVP or desmopressin
Active cardiovascular disease or unstable angina
Hyponatremia or history of hyponatremia
Current or historical deep venous thrombosis or pulmonary embolism
Intervention: Tagatose
Trial phase: Phase 2
SMILES: O=C(CO)[C@@H](O)[C@@H](O)[C@H](O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Low dose, 2.5 g TID premixed with drinking water into a solution of 4 oz per dose.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetics in accordance with WHO.
Male and female patients, between 18 and 75 years of age.
Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.
Normal blood creatine clearance and normal liver function test results.
BMI less than or equal to 45 kg/m2

Exclusion Criteria:

Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.
Therapy with beta-blockers or thiazide diuretics within the prior 3 months
Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.
Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.
Receiving any investigational drug within 30 days of the baseline visit.
Intervention: Tagatose
Trial phase: Phase 2
SMILES: O=C(CO)[C@@H](O)[C@@H](O)[C@H](O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: 5.0 dose, 5.0 g TID premixed with drinking water into a solution of 4 oz per dose.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetics in accordance with WHO.
Male and female patients, between 18 and 75 years of age.
Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.
Normal blood creatine clearance and normal liver function test results.
BMI less than or equal to 45 kg/m2

Exclusion Criteria:

Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.
Therapy with beta-blockers or thiazide diuretics within the prior 3 months
Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.
Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.
Receiving any investigational drug within 30 days of the baseline visit.
Intervention: Tagatose
Trial phase: Phase 2
SMILES: O=C(CO)[C@@H](O)[C@@H](O)[C@H](O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: high dose. 7.5 g TID premixed with drinking water into a solution of 4 oz per dose.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetics in accordance with WHO.
Male and female patients, between 18 and 75 years of age.
Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.
Normal blood creatine clearance and normal liver function test results.
BMI less than or equal to 45 kg/m2

Exclusion Criteria:

Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.
Therapy with beta-blockers or thiazide diuretics within the prior 3 months
Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.
Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.
Receiving any investigational drug within 30 days of the baseline visit.
Intervention: Linolenic Acid
Trial phase: Phase 2
SMILES: CCC=CCC=CCC=CCCCCCCCC(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 16
Group description: The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.

Omega 3 Fatty Acids: The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
Eligibility criteria:
Inclusion Criteria:

12 to 19 years old (inclusive) of both sexes and all ethnic/racial groups.
DSM-IV-TR criteria for MDD
MDD Duration of at least 8 weeks and a severity score of at least 40 on the CDRS-R.
Age at first onset MDD of at least 12 years.
No significant medical or neurological disorder
For female subjects, negative pregnancy test at time of enrollment.
Female subjects who are sexually active and not using a method of birth control will be excluded. Use of hormonal contraceptives (such as prescribed "birth control pills" or a prescribed birth control implant) is not exclusionary.
Subjects must be able to swallow capsules.
A minimum IQ of 80 will be required.

Exclusion Criteria:

Current or Past DSM-IV-TR diagnoses of bipolar disorder, schizophrenia, psychosis, autism/pervasive developmental disorder (PDD), and Tourette's disorder (TD).
Current diagnosis of eating disorder, panic disorder, obsessive-compulsive disorder (OCD), post traumatic stress disorder (PTSD), conduct disorder, and substance related disorders other than nicotine.
Current suicidal ideation with intent or plan, or who may pose a danger to themselves.
Current antidepressant treatment will be excluded. Past antidepressant treatment will not be exclusionary, so long as patients are off antidepressant medication for 60 days prior to study entry. No individual will be advised to terminate ongoing treatment.
Certain short half-life medications, such as vitamins that contain unidentified ingredients, St. Johns Wort, S-adenosyl Methionine (SAM), clonidine, and some over-the-counter medications.
A minimum of 90 days off of treatment with long half life medications, such as neuroleptics, prior to study entry is required. Stimulant medication treatment for ADHD will not be exclusionary.
If adolescents have been in psychotherapy prior to their entry in the study, they will be allowed to continue with the treatment. However, psychotherapy cannot be initiated at the time of study entry.
Intervention: ANGIOTENSIN II
Trial phase: Phase 1
ATC code: C01CX09
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 28
Group description: Healthy controls

Angiotensin II: Angiotensin II infusion for 1 hour
Eligibility criteria:
Inclusion Criteria:

Diagnosis of postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center criteria
Age between 18-64 years
Male or females are eligible
Able and willing to provide informed consent
Healthy control subjects with no major medical problem (including postural tachycardia syndrome), free of medications during the study

Exclusion Criteria:

Overt cause of postural tachycardia e.g., dehydration
Inability to give or withdraw informed consent
Pregnancy
Hypertension (BP > 140/90)
Significant co-morbid condition
Other factors which in the investigator's opinion would prevent the subject from completing the protocol
Intervention: ANGIOTENSIN II
Trial phase: Phase 1
ATC code: C01CX09
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 28
Group description: Patients with Postural Tachycardia Syndrome

Angiotensin II: Angiotensin II infusion for 1 hour
Eligibility criteria:
Inclusion Criteria:

Diagnosis of postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center criteria
Age between 18-64 years
Male or females are eligible
Able and willing to provide informed consent
Healthy control subjects with no major medical problem (including postural tachycardia syndrome), free of medications during the study

Exclusion Criteria:

Overt cause of postural tachycardia e.g., dehydration
Inability to give or withdraw informed consent
Pregnancy
Hypertension (BP > 140/90)
Significant co-morbid condition
Other factors which in the investigator's opinion would prevent the subject from completing the protocol
Intervention: Malathion
Trial phase: Phase 3
ATC code: P03AX03
SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 206
Group description: Malathion gel 0.5% 30 minute application

Malathion gel 0.5%: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
Eligibility criteria:
Inclusion Criteria:

Confirmed active head lice infestation

Exclusion Criteria:

Allergy to pediculicides or hair care products
Scalp conditions other than head lice
Previous head lice treatment within the past 4 weeks
Current antibiotic treatment
Intervention: Carvedilol
Trial phase: Phase 1 | Phase 2
ATC code: C07AG02 | C07FX06
SMILES: COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI

Carvedilol: twice daily oral treatment in escalating dose
Eligibility criteria:
Inclusion Criteria:

idiopathic, familial or associated PAH, WHO group 1
NYHA class II or III
clinically stable with optimized PAH treatment for at least 3 months
no or minimal evidence of fluid overload or volume depletion, with or without diuretic treatment
age > 18 years
mean pulmonary artery pressure (mPAP) > 25 mmHg
6 minute walk distance (6MWD) over 100m

Exclusion Criteria:

Structural heart disease unrelated to PAH
Recent (<3 months) treatment with an intravenous positive inotropic agent
current use of β-blockers
history of reactive airways disease
history of adverse reaction to β-blockers
heart block on ECG or resting heart rate < 60 bpm
cardiac index < 1.8 l/min/m2
systemic hypotension (systolic pressure < 90 mmHg)
pulmonary capillary wedge pressure > 15 mmHg
inability to give informed consent
contraindications to CT and/or PET scanning
coagulopathy (INR>1.5 or platelet count<50000/mm3)
severe renal insufficiency (creatinine clearance <30 ml/min/m2)
malignancy or any co-morbidity limiting survival or conditions predicting inability to complete the study.
Intervention: Benztropine mesilate
Trial phase: Phase 2
SMILES: CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2.CS(=O)(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: anticholinergic medication; active placebo

benztropine mesylate 0.125 mg daily: benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
Eligibility criteria:
Inclusion Criteria:

Chronic back pain (daily pain for > 6 months)

Exclusion Criteria:

Major medical conditions which might contraindicate antidepressant treatment
Intervention: Atorvastatin
Trial phase: Not Applicable
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Participants received 20 mg atorvastatin given orally daily for the first 3 months, followed by 40 mg atorvastatin daily for the final 9 months.
Eligibility criteria:
Inclusion criteria:

Men and women age 18-60 with previously diagnosed HIV disease
Subclinical coronary artery disease as defined by presence of one or more plaque on coronary CTA without history of cardiac events or cardiac symptoms and no evidence of critical coronary stenosis. Target to background ratio (TBR) as determined by PET of > 1.6.
Stable anti-retroviral (ARV) therapy as defined by no changes in ARV regimen for >6 months
LDL-cholesterol >70 mg/dL and <130 mg/dL

Exclusion criteria:

History of acute coronary syndrome
Contraindication to statin therapy
Current statin use
AST or ALT two times greater than the upper limit of normal or receiving treatment for active liver disease
Renal disease or creatinine >1.5 mg/dL (given the risk of contrast nephropathy during CT angiography of the heart)
Infectious illness within past 3 months
Contraindication to beta-blocker (including moderate to severe asthma or heart block) or nitroglycerin use as these drugs are given as part of the standard cardiac CT protocol. Previous allergic reaction to beta blocker or nitroglycerin.
Body weight greater than 300 lbs due to CT scanner table limitations
Patients with previous allergic reactions to iodine-containing contrast media
Active illicit drug use

Patients who report any significant radiation exposure over the course of the year prior to randomization. Significant exposure is defined as:

More than 2 percutaneous coronary interventions (PCI) within 12 months of randomization
More than 2 myocardial perfusion studies within the past 12 months
More than 2 CT angiograms within the past 12 months
Any subjects with history of radiation therapy.
Patients already scheduled or being considered for a procedure or treatment requiring significant radiation exposure (e.g., radiation therapy, PCI, or catheter ablation of arrhythmia) within 12 months of randomization
Pregnancy or breastfeeding
Coronary artery luminal narrowing >70% seen on coronary CTA
Intervention: Melatonin
Trial phase: Phase 2
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 10
Group description: Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks

Melatonin: Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects.
Eligibility criteria:
Inclusion Criteria:

Age 6-11 years (prepubertal based on tanner staging)
Patients with epilepsy (diagnosis based on ILAE).
Normal intelligence based on school placement (defined as age appropriate; an IEP due to epilepsy related causes is acceptable as is placement in a higher grade) or IQ>70 (testing done with in 12 months of enrollment)
No history of significant snoring- loud snoring every night outside of a room with closed door
Combined score of 30 or more on sleep fragmentation, parasomnia and daytime drowsiness subscales on SBQ.

Exclusion Criteria:

History of significant snoring- loud snoring every night heard outside of a room with closed door
Diagnosis of obstructive sleep apnea (OSA) or periodic limb movement disorder on PSG
Vagus nerve stimulator implanted
History of a major psychiatric disease (e.g. psychosis, major depression)
History of autism or pervasive development disorder
Severe neuro-developmental disabilities, as determined by PI
Clinically significant systemic organic disease, as determined by PI
Current use of melatonin or sustained release melatonin
Prior use of sustained release melatonin
Current use of any hypnotic medications except for medications used as a rescue treatment for seizures
Use of psychoactive or stimulant medication for attention deficit disorders
Subjects with immune disorders, lympho-proliferative disorders, and those taking oral corticosteroids or other immuno-suppressants
Subject or parent/legal guardian might not be reasonably expected to be compliant with or to complete the study.